Last May, researchers at a pharmaceutical conference in Orlando, Florida had tears in their eyes as they were given a standing ovation from an audience of medical specialists. The emotion was sparked by early reports from researchers on a substantial medical trial which convinced them they were witnessing a fundamental breakthrough in the treatment of breast cancer.
Last Thursday, the results of trials were mapped out in full. And hopes appeared to be fully vindicated. The New England Journal of Medicine (NEJM) published conclusions from the first trials of Herceptin.
It reveals "a dramatic and perhaps permanent perturbation in the natural history of the disease, maybe even a cure." Those same researchers concluded that women treated with Herceptin had a 46 percent reduced risk of their breast cancer returning.
For Roche the news could be lucrative. The Swiss giant will own the drug and have it under patent for 20 years. Herceptin, if it continues through the trial process and gets regulatory approval, could boost Roche's annual revenue by a stunning ?2.5 billion, according to analysts, and will be a total vindication of its decision to invest in the biotechnology sector.
Before the trials had even been completed, Herceptin sales grew 58 percent to ?280 million. Herceptin treats an aggressive form of breast cancer known as Her-2 positive.
bow to pressure
In the UK, Health Secretary Patricia Hewitt said the drug would be available on the tax-funded National Health Service (NHS). She bowed to pressure after Barbara Clark, a 49-year-old nurse, threatened to take her local health authority to the European Court of Human Rights if it did not prescribe her the drug.
Hewitt's concession will benefit 5,000 of the 35,000 women with breast cancer in the UK.
However, according to the Herceptin Web site "administration can result in the development of certain heart problems, including congestive heart failure. Severe allergic reactions, infusion reactions, and lung problems have been observed."
But Denise Anderson, head of healthcare at Kepler Equities, said: "Roche is providing innovation. I could not care less about the hundreds of anti high-blood pressure products. This drug looks like it will literally give women a new lease of life."
The trials reported in the NEJM involved 3,000 women in the US and 5,000 women in 39 other countries who were randomly allocated treatment with Herceptin after chemotherapy.
As Roche thrives many of the world's other major drug firms are suffering. Pfizer, the world's biggest, is struggling with the loss of patents on key treatments and a healthcare scare linked to the arthritis drug Celebrex. The result saw a 52 percent slump in quarterly profits announced last week.
Pfizer has been criticized for a failure to produce new blockbuster drugs from its research and development unit despite an annual US$7 billion budget.
Meanwhile GlaxoSmithKline has struggled to integrate its US and UK managements after its mega-merger five years ago.
purpose: Tesla’s CEO sought to meet senior Chinese officials to discuss the rollout of its ‘full self-driving’ software in China and approval to transfer data they had collected Tesla Inc CEO Elon Musk arrived in Beijing yesterday on an unannounced visit, where he is expected to meet senior officials to discuss the rollout of "full self-driving" (FSD) software and permission to transfer data overseas, according to a person with knowledge of the matter. Chinese state media reported that he met Premier Li Qiang (李強) in Beijing, during which Li told Musk that Tesla's development in China could be regarded as a successful example of US-China economic and trade cooperation. Musk confirmed his meeting with the premier yesterday with a post on social media platform X. "Honored to meet with Premier Li
Dutch brewing company Heineken NV on Friday announced an investment of NT$13.5 billion (US$414.62 million) over the next five years in Taiwan. The first multinational brewing company to operate in Taiwan, Heineken made the statement at a ceremony held at its brewery in Pingtung County. It also outlined its efforts to make the brewery “net zero” by 2030. Heineken has been in the Taiwanese market for 20 years, Heineken Taiwan managing director Jeff Wu (吳建甫) said. With strong support from local consumers, the Dutch brewery decided to transition from sales to manufacturing in the country, Wu said. Heineken assumed majority ownership and management rights
ARTIFICIAL INTELLIGENCE: The chipmaker last month raised its capital spending by 28 percent for this year to NT$32 billion from a previous estimate of NT$25 billion Contract chipmaker Powerchip Semiconductor Manufacturing Corp (力積電子) yesterday launched a new 12-inch fab, tapping into advanced chip-on-wafer-on-substrate (CoWoS) packaging technology to support rising demand for artificial intelligence (AI) devices. Powerchip is to offer interposers, one of three parts in CoWoS packaging technology, with shipments scheduled for the second half of this year, Powerchip chairman Frank Huang (黃崇仁) told reporters on the sidelines of a fab inauguration ceremony in the Tongluo Science Park (銅鑼科學園區) in Miaoli County yesterday. “We are working with customers to supply CoWoS-related business, utilizing part of this new fab’s capacity,” Huang said, adding that Powerchip intended to bridge
Microsoft Corp yesterday said that it would create Thailand’s first data center region to boost cloud and artificial intelligence (AI) infrastructure, promising AI training to more than 100,000 people to develop tech. Bangkok is a key economic player in Southeast Asia, but it has lagged behind Indonesia and Singapore when it comes to the tech industry. Thailand has an “incredible opportunity to build a digital-first, AI-powered future,” Microsoft chairman and chief executive officer Satya Nadella said at an event in Bangkok. Data center regions are physical locations that store computing infrastructure, allowing secure and reliable access to cloud platforms. The global embrace of AI